[Study of antileukemic effect of CpG-oligodeoxynucleotides treated cord blood].
OBJECTIVE
To observe the antileukemic effect of lymphocytes from cord blood treated by CpG-oligodeoxynucleotides (CpG-ODN).


METHODS
Lymphocytes from cord blood were exposed to different oligodeoxynucleotides containing a panel of CpG-ODN and were cultured with K562 cells. The cytotoxic effects were detected by MTT method. Immunological markers of cord blood treated by CpG-ODN(3) which showed highest activity were measured with flow cytometry.


RESULTS
Different CpG-motifs have different immunostimulatory activity and CpG-ODN(3) has the highest one. After treated by CpG-ODN(3), NK killing activity to K562 cells increased in a dose-dependent manner, and CD(3), CD(4), CD(19) and CD(56) increased to (60.6 +/- 7.9)%, (40.2 +/- 3.5)%, (22.4 +/- 1.9)% and (15.5 +/- 3.1)%, respectively.


CONCLUSIONS
CpG-ODN could reinforces the immunological competence of cord blood lymphocytes and their effects on K562 cells. This provides a new approach to reinforce the antitumor effects of cord blood.
Chen
Chun-yan
CY
Department of Hematology and Oncology, the Second Hospital of Shandong University, Jinan 250033, China.
Jia
Ji-hui
JH
Pan
Xiang-lin
XL
Zhou
Ya-bin
YB
Zhao
Wei-ming
WM
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D015703:Antigens, CD / Q000097:blood; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D005312:Fetal Blood / Q000166:cytology*; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000628:therapy*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides